Premal Patel is a physician-scientist with over 15 years of experience in medical oncology drug development, thoughtfully combining clinical strategy with adept biomarker approaches. Most recently, Premal has worked to advance immunotherapy and cell therapy at Lyell Immunopharma (as CMO) and at Juno Therapeutics (as SVP, Head of Early Clinical Drug Development) where he led CART efforts in multiple myeloma and all solid tumor CART & TCR efforts. Prior to this, he was VP, Head Early Clinical Development and Translational Research at Pfizer, where he led the allogeneic CART effort, along with ~15 immuno-oncology assets.
He spent over 7 years at Genentech, Research and Early Development leading clinical development for several agents, including: aPD-L1+Avastin in renal cell carcinoma and AKT inhibitor (ipatasertib) across multiple indications from preIND to successful proof-of-concept at end of randomized Phase 2 trials.
Premal received B.S. in pharmacy from Rutgers University; M.D. and Ph.D. degrees at University of Washington. He completed internal medicine at University of Washington and adult medical oncology at Memorial Sloan Kettering Cancer Center, where he researched targeted therapies for renal cell carcinoma. During his spare time, he volunteers as Chair of the Scientific Advisory Board for Fanconi Anemia Research Fund (an inherited disease resulting in inability to repair DNA crosslinks and thus cancer predisposition at a young age).